RSS-лента DailyMed Drug Label Updates for ALDURAZYME (LARONIDASE) INJECTION, SOLUTION, CONCENTRATE [GENZYME CORPORATION]

Больше RSS-лент с сайта dailymed.nlm.nih.gov

• dailymed.nlm.nih.gov https://dailymed.nlm.nih.gov/dailymed/rss.cfm
• DailyMed Drug Label Updates for SAPHNELO (ANIFROLUMAB) INJECTION, SOLUTION [ASTRAZENECA PHARMACEUTICALS LP] https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=d6203302-2128-41a7-b0b4-0e6c0704d4dc
• DailyMed Drug Label Updates for GAZYVA (OBINUTUZUMAB) INJECTION, SOLUTION, CONCENTRATE [GENENTECH, INC.] https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda
• DailyMed Drug Label Updates for the SIMPONI (GOLIMUMAB) INJECTION, SOLUTION [JANSSEN BIOTECH, INC.] https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=f86cb4a7-c358-4136-ae57-b32bda9bba00
• DailyMed Drug Label Updates for the ILUMYA (TILDRAKIZUMAB-ASMN) INJECTION, SOLUTION [SUN PHARMACEUTICAL INDUSTRIES, INC.] https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=c6a322bb-51b9-4f0e-8642-62a9682ffcde
• DailyMed Drug Label Updates for RIABNI (RITUXIMAB-ARRX) INJECTION, SOLUTION [AMGEN INC] https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=da1c4de7-0e5b-4f72-97ec-7a8d368f085f
• DailyMed Drug Label Updates for SOLU-CORTEF (HYDROCORTISONE SODIUM SUCCINATE) INJECTION, POWDER, FOR SOLUTION [PHARMACIA & UPJOHN COMPANY LLC] https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=65eefd58-b166-4d71-ade6-45c8fdf86922
• DailyMed Drug Label Updates for SPRAVATO (ESKETAMINE HYDROCHLORIDE) SOLUTION [JANSSEN PHARMACEUTICALS INC.] https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed

Все RSS-ленты сайта dailymed.nlm.nih.gov

Другие RSS-ленты

• ClinicalTrials.gov: RPC-1063 (ozanimod) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days clinicaltrials.gov
• ClinicalTrials.gov: UPLIZNA | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days clinicaltrials.gov
• ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days clinicaltrials.gov